Core Viewpoint - Bumiputra (Beijing) Investment Fund Management Co., Ltd. focuses on "professional financing and stable returns" to provide safe, efficient, and sustainable wealth enhancement services for investors [2] Group 1: Company Overview - The company relies on a professional team and rigorous risk control system, demonstrating exceptional capabilities in financing management, asset allocation, and investment strategies [2] - Through in-depth market analysis and precise project selection, the company identifies high-quality assets to efficiently connect funds with projects [2] Group 2: Risk Management - The company emphasizes risk control by employing diversified investment portfolios and dynamic adjustment strategies to minimize the impact of market fluctuations, ensuring stable returns for investors [2] Group 3: Client-Centric Approach - Bumiputra adheres to a "people-oriented, integrity first" business philosophy, providing customized financial service solutions based on client needs [2] - Whether for corporate financing or personal wealth management, the company adopts a professional and prudent attitude to create long-term and stable investment returns for clients [2] Group 4: Future Outlook - The company plans to deepen industry research, expand cooperation areas, and continuously improve service levels to help investors achieve their wealth dreams [2]

Group 1 - The Shanghai Composite Index has reached a nearly 10-year high, surpassing the 3800-point mark, with market turnover exceeding 2 trillion yuan, indicating high market enthusiasm [1][2] - The current market rally is driven by multiple factors, including supportive policies, breakthroughs in domestic technology companies, and improved market confidence [2][3] - Compared to previous peaks, the current market structure shows significant differences, with a shift from consumer and pharmaceutical sectors to technology and cyclical industries [2][3] Group 2 - The current economic cycle is characterized by a focus on new productive forces, with significant advancements in technology and manufacturing sectors [6][14] - The market is expected to transition into a sustainable "slow bull" phase, with opportunities arising from ongoing macro policies, liquidity conditions, and improving corporate earnings [4][5] - Investment strategies are shifting towards a balanced approach, focusing on both growth sectors like AI and high-end manufacturing, as well as undervalued blue-chip stocks [9][10] Group 3 - Key investment opportunities are identified in sectors benefiting from new productive forces, AI applications, and the "anti-involution" policy, which aims to optimize supply-side structures [11][12] - The technology sector, particularly AI and innovative pharmaceuticals, is expected to continue its strong performance, while traditional sectors also present opportunities due to global competitiveness [7][11] - The market's valuation is currently reasonable, but there are concerns about potential overheating in certain segments, necessitating careful monitoring of corporate earnings and policy impacts [15][16]

Group 1: Ice Wheel Environment (冰轮环境) - The company aims to promote global sustainable development, focusing on artificial environment control technology and energy utilization technology [1] - In the first half of 2025, the company achieved operating revenue of 3.12 billion yuan, a year-on-year decline of 7%, and a net profit attributable to shareholders of 266 million yuan, down 20% year-on-year [1] - Main products include compressors and heat exchangers, with a full range of magnetic suspension compressor products covering a temperature range of -271℃ to 200℃ [1] - The company provides cooling equipment for data centers and has developed technologies for nuclear power cooling and waste heat recovery [1] - Successfully developed a helium compressor for controlled nuclear fusion applications [1] Group 2: Sanwei Chemical (三维化学) - The company is a technology-driven chemical group involved in chemical and petrochemical technology R&D, engineering services, and catalyst production [1] - In the first half of 2025, the company reported total revenue of 1.25 billion yuan, a year-on-year increase of 21.81%, and a net profit of 120.36 million yuan, up 42.54% year-on-year [1] - The company has signed uncompleted orders worth 1.63 billion yuan in its engineering business [1] - It employs a flexible production model and is advancing projects to optimize cellulose acetate products and upgrade cellulose derivatives [1] - The company plans to distribute cash dividends of 1.00 yuan per 10 shares, totaling 64.89 million yuan [1] Group 3: Furuya Co., Ltd. (福瑞股份) - The company announced a strategic collaboration with Novo Nordisk to promote the early diagnosis and treatment of MASH following the approval of semaglutide for a new indication [2] - Orders are sufficient despite not yet receiving feedback from distributors and hospitals regarding the new indication [2] - The company is focused on its established goals and will not adjust its strategies or action plans [2] - The North American market is experiencing good growth, driven by the new drug approval and increased awareness [2] - The performance in traditional Chinese medicine has improved mainly due to e-commerce growth and increased demand for liver protection [2] Group 4: Jin Ying Fund (金鹰基金) - As of now, the fund has an asset management scale of 68.025 billion yuan, ranking 74th among 210 [3] - The fund has 156 public funds under management, ranking 50th among 210 [3] - The best-performing fund in the past year is Jin Ying Technology Zhi Yuan Mixed A, with a net value of 1.88 and a growth of 95.67% [3] - The latest public fund product launched is Jin Ying Zhong Zheng Quan Zhi Zi You Xian Jin Liu Zhi Shu A, which is an index-type stock fund [3]

Group 1 - The Hua Bao Shen Zhen Innovation 100 ETF will hold a communication-based meeting from August 4 to August 22, 2025, to discuss the transformation and modification of the fund contract [1] - The fund will suspend trading from the date of the meeting's vote counting on August 25, 2025, until the announcement of the voting results on the following day at 10:30 AM [1] - Investors are advised to pay attention to liquidity risks during the suspension period [1] Group 2 - Hua Bao Fund Management Company has added Kaiyuan Securities as a sales agency for the Hua Bao Hang Seng Hong Kong Stock Connect Innovative Drug Selection ETF starting August 25, 2025 [3] - Investors can conduct account opening, subscription, redemption, and other services through the new sales agency [3][4] - The company has also added Shanxi Securities as a sales agency for the same fund effective from August 25, 2025 [7] Group 3 - Hua Bao Fund Management Company has added Huafu Securities as a sales agency for the Hua Bao Zhongzhai 0-2 Year Policy Financial Bond Index ETF starting August 25, 2025 [10] - Investors can perform various transactions through Huafu Securities as well [10][11] Group 4 - To enhance market liquidity and stable operation, Hua Bao Fund Management Company has appointed Guotai Haitong Securities as a liquidity service provider for the Hua Bao Entrepreneurial Board Artificial Intelligence ETF and the Hua Bao S&P Hong Kong Stock Connect Low Volatility Dividend ETF starting August 25, 2025 [12]

Core Points - Guohe Xinli (Beijing) Fund Management Co., Ltd. is a legally established and independently operated private fund management institution [1] - The company has identified illegal activities where fraudsters are misusing its name to conduct scams, including issuing false fixed-income products and illegal fundraising [1] - The company has issued multiple statements since 2023 on its official website to clarify these facts and warn the public to be vigilant against scams [1] Summary by Sections - **Company's Position on Fraud** - The company has not authorized any individual or organization to represent it in fundraising or legal agreements [1] - Any claims of representation must be supported by valid authorization documents signed by the company's legal representative [1] - Unauthorized actions may constitute criminal fraud, and the company does not bear legal responsibility for such actions [1] - **Public Advisory** - The company urges the public to remain vigilant and report any instances of individuals or organizations misusing its name [2] - Contact information for verification is provided, including a phone number and email address [2] - The company reserves the right to pursue legal action against all illegal activities [2]

根据诺安基金管理有限公司（以下简称"本公司"）与兴业银行股份有限公司（以下简称"兴业银行"）签 署的基金销售服务协议，自2025年8月25日起，本公司旗下部分基金增加兴业银行银银平台为销售机 构。现将相关事项公告如下： 一、适用基金及基金业务开通情况 ■ 投资者可通过兴业银行银银平台办理上述基金的申购、赎回、定期定额投资、转换等业务，进行相关信 息查询并享受相应的售后服务，具体的业务流程、办理时间及办理方式以兴业银行银银平台的规定为 准。 二、基金费率优惠活动 投资者通过兴业银行银银平台办理上述基金的申购、定投申购业务，享有的申购费费率优惠以兴业银行 银银平台的规定为准。 投资者通过兴业银行银银平台办理上述基金与本公司旗下可参与转换基金间的转换业务，享有的申购费 补差费率优惠以兴业银行银银平台的规定为准。 基金费率标准详见最新的招募说明书、基金产品资料概要等法律文件，以及本公司发布的最新业务公 告。 5、本公告的有关内容在法律法规允许范围内由本公司负责解释。 投资者可通过以下途径咨询有关情况： 1、兴业银行股份有限公司 客服电话：95561 网址：www.cib.com.cn 2、诺安基金管理有限公司 重要提 ...

Group 1 - The fund is named "Oriental Red Medical Innovation Mixed Securities Investment Fund (QDII)" and is a mixed-type open-ended fund approved by the China Securities Regulatory Commission (CSRC) [1][18] - The fund's minimum total subscription amount is set at 200 million units, and the minimum fundraising amount is 200 million RMB, excluding interest [6][17] - The fundraising period is from September 10, 2025, to September 23, 2025, with the possibility of extension not exceeding three months [5][19] Group 2 - The fund offers two classes of shares: Class A and Class C, with different fee structures. Class A charges subscription fees, while Class C does not charge subscription fees but incurs service fees from the fund's assets [5][25] - The minimum subscription amount for each class of shares is set at 10 RMB when processed through the fund manager's direct sales center [11][22] - Investors must use the company's open-end fund account for subscription, and those without an account can open one through direct or agent sales institutions [4][29] Group 3 - The fund primarily invests in publicly listed companies in the medical innovation sector, aiming to achieve returns that exceed the performance benchmark while strictly controlling investment risks [18] - The fund's management is conducted by Shanghai Oriental Securities Asset Management Co., Ltd., with Shanghai Pudong Development Bank as the custodian [3][51] - The fund's net asset value may fluctuate due to market volatility, and investors are encouraged to read the fund's prospectus and related documents for detailed information [9][7]

Core Insights - The article emphasizes the importance of sustainable dividends and high-quality earnings in dividend investment strategies, particularly in the context of a low-interest-rate environment and market volatility [1][2][3] Group 1: Investment Strategy - The high dividend strategy focuses on selecting stocks with high dividends, low valuations, and strong earnings quality, while also considering future profitability and dividend plans [1][2] - The strategy is built around two dimensions: mature, low-valuation leading companies with stable cash flows and high dividend-paying "small but beautiful" companies with growth potential [2][3] - The average dividend yield of the top ten holdings in the fund managed by the company is reported at 6.08% as of the end of Q2 [2] Group 2: Quantitative Approach - The introduction of quantitative methods enhances the high dividend strategy, utilizing multi-factor models and machine learning for stock selection and risk optimization [4][5] - The company employs a "core + satellite" multi-strategy approach, where the core focuses on high dividends and low valuations, while the satellite includes various defensive strategies to diversify risk [5][6] - Machine learning, particularly neural network strategies, is increasingly integrated into quantitative strategies to improve stock selection metrics [5][6] Group 3: Team and Collaboration - The quantitative investment team has been focused on strategy development since 2011, combining expertise from mathematics, computer science, and financial engineering [6] - The team operates on a collaborative platform where data and strategies are shared, allowing for systematic analysis and optimization of investment strategies [6] - The integration of data-driven decision-making reduces subjective influences and enhances the efficiency of investment operations [6]

Group 1 - The report highlights a shift in A-share ETF investments towards net buying, with a recommendation to focus on innovative drug ETFs [2][3] - The "Xinxuan ETF Absolute Return Strategy" has shown impressive performance, achieving a total return of 46.92% since the beginning of 2024, outperforming equal-weighted ETFs by 12.35% [10][33] - The "All-Weather Multi-Asset Risk Parity Strategy" has yielded a return of 22.65% with a maximum drawdown of 3.62% since the beginning of 2024 [12][33] Group 2 - The report tracks the new issuance of index funds, noting that 38 new public funds were established this week, raising a total of 233.14 billion yuan, with 26 index funds accounting for 167.53 billion yuan [38] - The report details the net inflow of funds into various asset class ETFs, with A-share ETFs seeing a net redemption of 10.1 billion yuan, while bond ETFs experienced a net inflow of 117.4 billion yuan [46][51] - The "High Prosperity/Dividend Rotation Strategy" has achieved an annualized return of 23.31% since the beginning of 2021, significantly outperforming equal-weighted indices [24][33]

据悉，商健拥有超过18年的金融行业从业经验，曾先后任职于陕西省国际信托投资股份有限公司、健桥证券股份有限公 司、信达证券股份有限公司（以下简称"信达证券"）等金融机构，历任信达证券董事会秘书、信达证券副总经理等核心管理岗 位，在战略规划、风险控制及公司治理等方面有丰富的实操经验。 8月23日，信达澳亚基金管理有限公司（简称"信达澳亚基金"）发布董事长离任及代行董事长职务的公告。公告显示，信 达澳亚基金原董事长祝瑞敏因工作安排于8月22日离任，董事长职务由商健代为履行。 （编辑 张昕） 本报记者 方凌晨 信达澳亚基金成立于2006年6月份，是经中国证监会批准设立的国内首家由国有资产管理公司控股的基金管理公司。2015 年5月22日，信达证券受让中国信达资产管理股份有限公司持有的股权（持股比例54%），与East Topco Limited共同持有信达澳 亚基金股份（持股比例46%）。Wind资讯数据显示，截至2025年二季度末，信达澳亚基金的管理规模为1030.06亿元，其中非 货基金管理规模为681.11亿元。 ...